Other studies proved that the progression of malignant melanoma is not associated with high expression of BCL2 [66], so it is better to evaluate the BAX/BCL2 ratio in determining sensitivity to apoptotic stimuli in melanoma [67]. The gene discussed is BAX; the disease is melanoma.